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Glioblastoma (GBM) is the most common form of brain tumor characterized by its resistance
to conventional therapies, including temozolomide, the most widely used chemotherapeutic
agent in the treatment of GBM. Within the tumor, the presence of glioma stem cells (GSC)
seems to be the reason for drug resistance. The discovery of GSC has boosted the search for
new experimental models to study GBM, which allow the development of new GBM
treatments targeting these cells. In here, we describe different strategies currently in use to
study GBM. Initial GBM investigations were focused in the development of xenograft assays.
Thereafter, techniques advanced to dissociate tumor cells into single-cell suspensions, which
generate aggregates referred to as neurospheres, thus facilitating their selective expansion.
Concomitantly, the finding of genes involved in the initiation and progression of GBM tumors,
led to the generation of mice models for the GBM. The latest advances have been the use of
GBM organoids or 3D-bioprinted mini-brains. 3D bio-printing mimics tissue cytoarchitecture
by combining different types of cells interacting with each other and with extracellular matrix
components. These in vivo models faithfully replicate human diseases in which the effect of
new drugs can easily be tested. Based on recent data from human glioblastoma, this review
critically evaluates the different experimental models used in the study of GB, including cell
cultures, mouse models, brain organoids, and 3D bioprinting focusing in the advantages and
disadvantages of each approach to understand the mechanisms involved in the progression
and treatment response of this devastating disease.
Keywords: glioma stem cells, cell cultures of glioma cells, mouse models of glioblastoma, brain organoids,
3D bioprintingINTRODUCTION
Glioblastoma (GBM) is the most common and aggressive tumor of the central nervous system
(CNS) (1). It represents more than 60% of all brain tumors in adults and it is associated with a bad
prognosis. Also, the Central Brain Tumor Registry of the United State (CBTRUS) registered in 2019
(including dates ranged between 2012 and 2016) that GBM represents the 14.6% of all malignantJanuary 2021 | Volume 10 | Article 6142951
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more than female) by this disease (2, 3). Despite the efforts of
scientists and clinicians to increase the life expectancy of GBM
patients, survivors do not easily exceed the 15th month (3–5) and
the 5-year survival rate is as low as 5.8% (2, 3, 6). Furthermore,
the median age is 65, and the most affected age ranges from 75 to
84 (3, 6). Globally, the incidence of GBM is higher in some
specific areas over others, such as North America, the west and
north of Europe, and Australia (7). Several risk factors have been
studied as critical for GBM development such as constitutive
genetic factors, ionizing radiation, or reduced susceptibility to
suffer allergies and asthma. However, some inconsistencies
among the different studies reveal the need of further
investigations (8–11). These inconsistencies are likely to be
caused by the existence of different types of GBM, which
behave differently.
The World Health Organization (WHO) classified GBM in
2016 combining histopathological and molecular features (12).
GBM are now classified into three subtypes based on the
presence and absence of IDH mutations: GBM IDH-wild type
(90% of tumors), IDH-mutant (10%), and GBM IDH-NOS in
which a full IDH evaluation cannot be performed. GBM-IDH-wt
include three variants: giant cell glioblastoma, gliosarcoma, and a
novel and provisional variant, the epithelioid GBM characterized
by large epithelioid cells and the presence of the BRAF V600E
mutation (12, 13). Based on the expressions of genes, GBM have
been classified in Classical, Mesenchymal, Proneural, and Neural
(14). Classical GBM is characterized by an amplification of the
chromosome 7, the loss of chromosome 10, and an increase in
EGFR expression. In Mesenchymal subtype a focal deletion of
FN1 gene is observed affecting the AKT pathway, whereas the
NF-kB pathway is highly expressed. The Proneural subtype is
characterized by alterations of PDGFRA and point mutations in
IDH. In this subtype some genes such as SOX, DCX, ASCL1 are
affected. The Neural type is characterized by the presence of
neural markers such as NEFL or GABRA1 (14). Several genetic
alterations in GBM have been linked with recurrence and relapse.
Thus, recurrent glioblastoma shows a higher frequency of copy
number variations in several genes, particularly cell cycle genes,
an enrichment in the cyclin-dependent kinase inhibitor 2A/B
(CDKN2A/B) loss, and an excessive activation of cell cycle
pathway genes. Also, gen sets such as TERT promoter and
IDH1 mutation or tumor protein 53 (TP53) and IDH1
mutation (15).
Given the bad prognosis associated to this type of tumors, the
search for therapeutic tools that represent a real increase in the
survival rate has become the main goal in GBM research. Current
GBM treatment includes the complete surgical resection of the
tumor mass, followed by a combination of radiotherapy and
chemotherapy (16). In this context, it is reasonable to say that the
most significant development in clinical management of
glioblastoma over the past two decades has been the
groundbreaking trial of combining radiotherapy plus
temozolomide (TMZ) (17), which resulted in an increase in
the 2-year survival from 8% in patients with radiotherapy alone
to 20% in patients with the combined therapy. Despite thisFrontiers in Oncology | www.frontiersin.org 2improvement, effectiveness of treatment is variable from patient
to patient. Apparently, effectiveness of treatment depends on
several factors such as the tumor localization and size, or the
brain anatomical structures affected (18). Essentially, one of the
most relevant problems surrounding GBM is its infiltration into
the healthy brain tissue, which makes practically impossible to
perform a complete resection using surgical tools. In addition,
the posterior radiation and chemotherapy do not completely
eliminate all GBM cells (19). Thus, new insights in surgical tools
are being used to allow visualization of cells within the tumor and
improve the tumor mass resection. These are fluorescence-
guided microsurgery (20) or intraoperative MRI, and
ultrasound, which have been used in the surgical resection of
CNS gliomas with the goal of maximizing extent of resection to
improve patient outcomes (21). Regarding chemotherapy, TMZ
is still the most effective so far, however, several other
chemotherapeutic agents are being used, some of them
directed to modulate the activation and suppression of
signaling pathways altered in GBM. Examples of these new
treatments are nelfinavir, tipifarnib, tamoxifen, or enzastaurin
(22). These agents have proven not to be the most effective in
individualized treatments, nonetheless, considering the
molecular, cellular, histological, and genetic variances found in
GBM, a deep molecular characterization of the different tumors
could potentially allow the design of individualized therapies
using these agents.
A problem linked to the inefficacy of TMZ treatment in the
long term is that some cells within the tumor have the ability to
escape its action (23) as well as the complementary radiation
(24). These are the glioma stem cells (GSC). These cells share
many similarities with Neural Stem Cell (NSCs) present within
the physiological neurogenic niche of the subventricular zone
(SVZ). These similarities are principally self-renewal and
differentiation capacity (25, 26) in addition to several
neurogenic markers, such as CD133 (27), nestin (28, 29),
CD15 (30, 31), or some transcriptional factors including Sox2,
Olig2, Nanog, and c-Myc (32). The first evidences on the role of
the SVZ harboring malignant GBM cells were obtained using
fluorescence guided resection of GBM using the commonly used
fluorescent marker 5-aminolevulinic acid (5-ALA). These
resections reveal the presence of fluorescent cells not only
within the tumor mass but also in the adjacent SVZ, thus
suggesting the presence of malignant cells in the SVZ of GBM
patients (33). Clonal analysis of the stem cell populations
suggested a GBM evolution as a result of multiple, genetically
diverse clonal and sub-clonal populations involving both the
SVZ and the tumor mass (33, 34). The role of the SVZ as a place
of origin of GBM has gained strength because of the similarities
between GSC and NSC of the SVZ (35). Vasculature, hypoxia,
and several growth factors that promote GSC proliferation have
been deeply studied in order to clarify the role of the SVZ in the
origin of GBM (36–38). The human SVZ is characterized by
presenting a complex cytoarchitecture composed of layers that
provide a good environment to proliferation and differentiation
of NSC (39, 40). In 2018, Lee et al. showed, using single-cell
sequencing, that astrocyte-like NSC in the healthy SVZ tissue ofJanuary 2021 | Volume 10 | Article 614295
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of migrating from the SVZ to lead the development of high-grade
malignant gliomas in distant brain regions (35).
Over the past years a vast set of methodologies have been used
in the study of GBM, leading to most of our current knowledge
on tumor development and prognosis (41) (Figure 1 and Tables
1, 2). However, the past 10 years have been crucial in the
development on new and innovative techniques, such as the
growth of GBM organoids, which are leading to novel and
individualized therapies (Figure 2 and Table 3) for the
treatment of this disorder (99, 127). In here, we discuss some
classical methodologies together with the description of the most
recently developed techniques to study GBM.CLASSICAL APPROACHES IN THE STUDY
OF GLIOBLASTOMA
Cell Cultures of Glioblastoma Cells
One of the most important tools in the study of GBM has been
the use of cell cultures. Cell cultures provide the maintenance of
cells in vitro for research and clinical studies, however it is
important to choose appropriately the cell line and culture
because none of the currently available cell-based gliomaFrontiers in Oncology | www.frontiersin.org 3model sys tems is ab le to reproduce the complex
microenvironment of glioma cells within the brain. Thus, each
in vitro model has its advantages and disadvantages and it is
necessary to select the cell system appropriate for each
experimental question (128). Some of these systems have been
widely used not only in the study of GSC but also in the study of
NSC giving a great deal of information about the physiology of
these cells (129–132) or about the finding of small
pharmacological molecules that regulate these activities (133).
Glioblastoma Cell Lines
The first studies using cell-based glioma model systems used cell
lines derived from induced Wistar/Furth rats and C57BL/6
mouse tumors of the central and peripheral nervous system
(42, 43). Later on, human GBM cells were also immortalized for
its use in culture (44, 45). This allowed the better understanding
of glioma cell biology by simplifying the studies, since glioma cell
lines provided an unlimited supply of cells available without
ethical concerns and the possibility of obtaining reproducible
results. Most commonly used human GBM immortalized cell
lines are U87MG, U252, T98G, and LN-229. These cell lines
show enrichment of cancer stem cells when grown as spheres in
serum containing medium (134). To date, it is the fastest way to
obtain preliminary results regarding the test of new anti-tumor
drugs in vitro. GBM cell lines are easy to manipulate and toA B
C D E
FIGURE 1 | Drawing summary of classical models currently in use to study GBM. Tumor samples resected from patients upon surgery are used to (A) generate
immortalized cell lines that can be maintained in time; (B) select GSC by culturing these cells as neurospheres under floating conditions; (C) produce xenograft
models by transplanting either cultured isolated cells or tumor tissue; (D) perform genomic analysis to select candidate genes to produce genetically modified
mice models of GBM; (E) canine models are good model for the study of GBM based on their analogies with human GBM.January 2021 | Volume 10 | Article 614295
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Method of study Advantage Disadvantage References
GBM cell lines • Good method to
understand GBM biology
• Simple system provided
with a single type of cells
• Less ethical concerns
• Reproducibility
• Fast method to obtain
preliminary results
• Easy to manipulate












Fields et al. (42), Sundarraj et al. (43), de Ridder et al. (44), Notarangelo et al. (45),







• Genotype and phenotype
characteristics resemble
those of primary tumors
• Give more comparable
results
• Can be maintained in vitro











• Introduce errors in
terms of clonality, size,
and number of
neurospheres
Sottoriva et al. (49), Jiang et al. (50), Linkous et al. (51), Lee et al. (52), Brewer et al.
(53), Baskaran et al. (54), Jayakrishnan et al. (55), Wang et al. (56), Chen et al. (57),
Mori et al. (58), Ladiwala et al. (59), Pollard et al. (60), Fael Al-Mayhani et al. (61),
Rahman et al. (62).
Xenograft model
of GBM
• Allow personalized drug
efficiency tests in single
patients




• A nude mouse is
necessary to develop
this model




• Does not reproduce
the original niche.
• It is not allow to test
immunomodulatory
therapies
Shu et al. (63), Lee et al. (52), Tentler et al. (64), Joo et al. (65), Patrizii et al. (66),
Ashizawa et al. (67), Hutchinson et al. (68), Son et al. (69), Khaddoui et al. (70),







• Modified models offer the
ability to directly alter the
genome of somatic cells in
mouse tissues introducing
or removing specific genes
• Reproduce pre-clinical
features






models are often not
representative of the
original human tumor
Furnari et al. (72), Holland et al. (73), Uhrbom et al. (74), Wei et al. (75), Baker et al.
(76), Miyai et al. (77).
Canine model of
GBM
• Similarities with human
glioma
• Good tool to perform pre-
clinical studies
• Ethical issues
• Difficult to detect
GBM in canine
models




• Good model to study
invasiveness
• * Niche similarities
• * Not reproduce
interactions with blood
flow factors or typical
hypoxic conditions
Eisemann et al. (83), Sliwa et al. (84); Marques-Torrejon et al. (85), Ravi et al. (86)
Brain organoids • Provide a powerful tool for
the ex vivo study of the
molecular and cellular
mechanisms
• Maintain the architecture
and organization of tissues
• Difficult approach in
terms of technology
• Need biopsies of
patients
• Complex structures to
maintain
Lancaster and Knoblich (87), Clevers (88), Chen et al. (89), Sasai (90), Huch et al.
(91); Hubert et al. (92), da Silva et al. (93), Ogawa et al. (94), Bian et al. (95), Krieger
et al. (96), Linkous et al. (51), Hwang et al. (97), Jacob et al. (98), Zhang et al. (99),
Perrin et al. (100), Vlachogiannis et al. (101), Ooft et al. (102), Ganesh et al. (103),
da Hora et al. (104).
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cell lines do not provide a reliable model to understand the
cellular and molecular mechanism underlying the development
of GBM or to evaluate therapeutic interactions because it fails to
represent the native tumor microenvironment. In addition, the
use of glioma cell cultures holds other issues intrinsic to
immortalized cell lines. Successive cell passages select cells
which have the highest proliferative potential, decreasing the
genetic heterogeneity found in the parental tumor (46). It is likely
that the selection imposed by the passages in in vitro cultures
result in genetic drift, accumulation of chromosomal aberrations,
and phenotypic alterations in cell lines (47, 48). Because of these
drawbacks, biobanks containing annotated and validated cell
lines derived from surgical samples of GBM patients that
preserve GSC features are being developed. This strategy
provides an open resource for the study of a large part of GBM
diversity (135).
Usually, the use of cell lines is well received as an
approximation or as preliminary data but it is necessary the
use of other models closer to reality to obtain more relevant and
representative data. However, these cultures have been
fundamental to solve and understand GBM biology (Figure 1A
and Table 1).
Patient-Derived Cells
Most cancers, including GBM, display intratumor heterogeneity
and this could be one of the reasons why some tumors lack of
satisfactory treatment (49, 50). Thus, the use of primary cell
cultures derived from patients may facilitate the individualized
study of GBM. Evidences show that the GSC subpopulation of
GBM are very important to maintain tumor heterogeneity, as
well as, the tumor initiation, maintenance, and invasion in vivoFrontiers in Oncology | www.frontiersin.org 5because of their capacity of self-renewal and differentiation (51).
So far, GSC cultures have become the most accepted standard for
studying GBM biology in vitro (52).
One of the problems found when using patient derived
cultures is the use of serum since the subpopulation of GSC
within the GBM is not present in cell cultures after prolonged
serum exposure. GSC differentiate under these conditions, losing
many of primary tumor characteristics (52). To avoid this issue,
patient-derived GSC can be maintained in vitro under floating
conditions in a serum free medium in which they form
characteristic aggregates referred to as neurospheres. The
starting population of cells is usually plated as a single-cell
suspension in a non-adhesive substrate containing defined
media supplemented with fibroblast growth factor (bFGF) and/
or epidermal growth factor (EGF) (52, 53). However, it is
important to consider that useful life of patient-derived glioma
cell cultures is limited. After 20–30 passages cells start exhibiting
genomic and transcriptional changes in metabolic and signaling
pathways such as ribosomal synthesis, telomere packaging, or
Wnt signaling pathways among others (54). Interestingly, the
success rates of neurosphere cultures from gliomas is dependent
on tumor grade and genetics, being the low-grade glioma cell
cultures the most difficult to culture as neurospheres (55).
Despite its advantages, the neurosphere system presents a few
drawbacks inherent to this cell culture method. Quiescent GSC
may be lost with time since along the successive cell passages cells
with the highest proliferative potential are selected and the
subpopulation of quiescent GSC is deselected. This
subpopulation is particularly important because it is believed
to be responsible for chemotherapy and radiotherapy resistance
(56, 57). Moreover, to ensure clonality and multipotentiality of
neurospheres, cells should be seeded as single cells per well (58).TABLE 1 | Continued
Method of study Advantage Disadvantage References
• Preserve important features
of the original tumor
heterogeneity
• Useful to study GBM
pathology and drug
response
• Good method to design
personalized therapies and
treatments and, also, in
drug screening
• Elevated cost
3D bioprinting • Provide a cell network that
resembles reality in a very
faithful way
• Replicate the architecture of
tissues
• Good method to test drugs
effectively
• Good to analyze cell
signaling
• Good method to test drug
sensibility scanning










• Printing resolution still
needs to be improved
• Need of a bioprinter
• High cost
Roseti et al. (105), Heinrich et al. (106), Ananthanarayanan et al. (107), Xiao et al.
(108), Hermida et al. (109), Tang et al. (110)January 2021 | Volume 10 | Article 614295
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concentration of paracrine and cell-to-cell signals required for
cell growth and division are minimal under these conditions. On
the contrary, neurospheres obtained after plating multiple cells
per well show spontaneous locomotion resulting in cell
aggregation and producing errors in terms of clonality, size,
and number of neurospheres, thus leading to discrepancies in
results and conclusions (59).
Looking for an effective manner to cultivate GSC, some
reports describe a methodology to attach these cells onto a
surface to expand them in serum free medium as adherent 2D
cultures in the presence of growth factors EGF and bFGF (60,
61). The use of adherent 2D-cultures increases the efficiency of
culture expansion avoiding the differentiation and apoptosis
associated to the sphere cultures. Attached cells are more
exposed to growth factors used in cultures that maintain the
proliferative capacity (60). Other authors maintain that both
methods, sphere and adherent cultures, are equal and useful to
study GBM (62) and it is likely that a combination of both
models is the best strategy for the in vitro test of GBM drugs, orFrontiers in Oncology | www.frontiersin.org 6for the study of new specific markers of GBM malignancy
and progression.
Taking together all these facts prove the benefits of using this
neurosphere cultures, starting with the capacity to preserve
heterogeneity and also, to study the migration process and
initiation of a new tumor. All these considerations are not
present in cell lines models. However, the problem associated
with the loss of quiescent GSC could be unfavorable in some
studies. Nonetheless, this model allows the culture of cells from
single individual patients, facilitating the study of inter-
individual differences (Figure 1B and Table 1).
Xenograft Models of Glioblastoma
In vivo transplants of GBM in animal models have long been
used to study tumor development upon the engraftment of
human cells into immunodeficient mice. Transplants of patient
derived xenografts, in which dissociated tumor cells or tumor
tissue fragments are implanted into mouse brains have
successfully been used in murine models (Figure 1C). Mainly,
three types of mouse have been used, which are classifiedTABLE 2 | Current trends in mouse xenografts and allografts.
Reference Implantation type Cell type Tumor type Animal model Strategy used
Tateishi et al. (111) Orthotopic xenograft MGG152 Recurrent
GBM
SCID mice NAMPT inhibitor
HT1080 Fibrosarcoma




Szabo et al. (112) Orthotopic xenograft LNT-229 GBM Nude mice Neutralization with VEGF
or PlGF antibodyLN-308 GBM
Sharpe et al. (113) Orthotopic xenograft BT111 Primary GBM Nude mice Monoamine oxidase
B-activated pro-drugBT116 Primary GBM
Zhang et al. (114) Orthotopic xenograft LN-319 GBM NSG mice ErbB2/HER2-Specific
NK CellsOrthotopic allograft GL261 GBM
Parrish et al. (115) Heterotopic and orthotopic
xenograft
GBM12 Primary GBM Mdr1a/b−/−Bcrp1−/−










Orthotopic xenograft GBM164 Primary GBM SCID mice Bcl-xL inhibition with ABT263
U87MG GBM
Yuan et al. (118) Orthotopic xenograft Patient derived brain
tumor initiating cells
Primary GBM SCID mice ABT-888 and temozolomide
treatment
Chang et al. (119) Orthotopic xenograft LN229 GBM Nude mice Pyr3 treatment
U87MG GBM
Sun et al. (120) Orthotopic xenograft TT150630 Primary GBM B-NDG mice Palbociclib in treatment
TT150728 Primary GBM
Bejarano et al. (121) Heterotopic xenograft h676 Primary GBM Nude mice TRF1 Chemical Inhibitors
h543 Primary GBM
Guo et al. (122) Orthotopic allograft GL261, GL261 Red-
FLuc
and GL261-Luc2
GBM C57BL mice FTY720 treatment
Gravina et al. (123) Heterotopic and
orthotopic xenograft
U87MG GBM Nude mice RES529, a TORC1/TORC2
dissociative inhibitor
Zalles et al. (124) Orthotopic xenograft G55 GBM Nude mice Neutralization with
ELTD1 antibody
Jensen et al. (125) Orthotopic xenograft patient-derived GB
brain
tumor stem cells
Primary GBM SCID mice Afatinib and pacritinib
treatment
Yang et al. (126) Heterotopic and
orthotopic allograft
GL261 GBM C57BL/6 mice Bip inhibition and
ionizing radiationJanuary 2021 | Volume 10 | Article 614295
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unable to produce T cells; ii) non-obese diabetic severe combined
immunodeficiency (NOD-SCID) and SCID-beige mice, which
lack T and B cells; and iii) NOD-SCID IL2R-g null (NSG or
NOG) mice, which lack T, B, or NK cell activity (136). GBM
implantation is usually done in the subcutaneous flank location
(heterotopic implantation) facilitating the visual observation of
tumor development, which allows testing the efficacy of anti-
tumor drugs by analyzing the tumor dimensions. However, an
important limitation to heterotopic models is that the established
microenvironment has an important role in GBM tumors. For
this reason, xenografts based on the implantation of GBM in the
brain (orthotopic implantation) are more extensively used
nowadays because it provides a CNS microenvironment, and
preserves the integrity of tumor-initiating cells (63). We have
summarized in Table 2 series of studies involving PDX models,
showing how orthotopic or heterotopic xenografts have been
used in different immunodeficient mouse strains to perform
preclinical studies on the efficacy of novel drug treatments.
Invasive xenografts have been established from surgical
specimens that were first maintained as tissue spheroids in
short-term culture to obtain cell lines (137, 138). Many human
and mouse cell lines have been used in PDX models (111, 112,
139, 140). The patient-derived cells are engrafted intoFrontiers in Oncology | www.frontiersin.org 7immunocompromised mice to maintain the histopathologic,
genomic, and phenotypic characteristic of the primary tumor
across early passages (64–66). Lee et al. used GSC lines to initiate
tumors in mice and they found a high percentage of
engraftments compared with patient derived tumor xenografts.
This type of tumor induction was much more potent and
maintained the heterogeneity typical of GBM (35, 67). While
NSC implantation into nude mice does not result in tumor
formation, GSC implantation leads to the generation of tumors
in a healthy brain, preserving tumor heterogeneity. This strategy
opens the possibility to development of personalized drugs
facilitating individual drug-screening and the search for
resistance mechanisms. Notwithstanding, several drugs
showing favorable results in pre-clinical studies using PDX
have failed posteriorly in clinical trials (68). Indeed, this is not
completely surprising since orthotropic implantation in PDX
models does not reproduce the conditions of the niche of origin.
The human stroma and microenvironment are not similar to
those in the mouse, limiting the study to tumor biology and
therapy resistance (69). Moreover, since these mouse models lack
inflammatory responsive cells or an intact immune system it
does not allow testing for immunomodulatory therapies. This
limitation is currently critical since immune therapeutics have




FIGURE 2 | Drawing summary of novel models currently in use to study GBM. (A) 3D Cultures of cells embedded in Matrigel have been key techniques in the
development of brain organoids; (B) growth of 3D structures using microfluidic systems replicates the changing microenvironment surrounding GBM in the
human brain; (C) GBM cells can be grafted in vitro in human brain slices grown as organotypic cultures replicating the natural environment of a GBM tumor;
(D) culture GBM organoids by either using glioma cells or by inserting GSC into brain organoids; (E) bio-print GBM 3D-spheroids using extracellular matrix
materials and other cell types.January 2021 | Volume 10 | Article 614295
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immune therapeutics for cancer treatment over the past few
years (70, 71).
Among the advantages of these xenograft models three can be
highlighted: i) they allow personalized drug efficiency tests in
single patients, ii) the original tumor architecture and
histological characteristic are preserved and iii) they are
genetically stable (Tables 1 and 2). However, there are
important caveats that need to be addressed in xenograft
models: i) immunodeficient rodents may not respond to
certain drugs, ii) the surrounding microenvironment of mouse
origin may interfere with drug response, and iii) they do not
allow the test of immune therapies, thus limiting the type of
drugs to be tested.
Genetically Engineered and Viral Vector-
Mediated Transduction Mouse Models
As mentioned before, several genetic alterations have been found
after the analysis of large numbers of uncultured GBM tissue
samples removed from patients, leading to the discovery of
several genes commonly mutated in GBM. Some of these
mutations are already present in common cancer genes, such
as EGFR, BRAF, RAS, PIK3CA, PIK3R1, PTEN (141, 142),Frontiers in Oncology | www.frontiersin.org 8particularly, EGFR variant III (EGFRvIII) is the most common
active EGFR mutant in GBM. The presence of this mutant
correlates with a poor patient prognosis due to its ability to
extend downstream signaling (143). Accordingly, kinases like v-
Src, which regulate the activity of these type of receptors have
also been involved proliferation and migration of glioma cells
(144). Additionally, a very clinically relevant discovery was the
finding of the IDH1 mutation appears in a high percentage of
secondary GBM and a small percentage of primary GBM (142).
While PTEN loss, and EGFR amplification, are associated with
primary glioblastoma, IDH1 mutation is common in secondary
glioblastoma and show a higher survival rate.
The study of genetic alterations has led to the development of
genetically engineered mouse models of GBM (77). Transgenic
mouse models and knockouts as well as vector-mediated genetic
approaches accurately reproduce pre-clinical features of GBM
including the accumulation of genetic and epigenetic alterations
in tumor suppressor genes or to the activation of oncogenic
pathways, which lead to the progression of tumors (72, 142, 145).
There are several examples employed in the development of
mouse glioma modelling of aberrant expression of relevant
downstream signaling pathways, resulting from i) expressing v-
src kinase under the control of glial fibrillary acidic proteinTABLE 3 | Current preclinical trials using organoids for the study of GBM.
Reference GBM organoid from Contribution to GBM study Potential clinical use Advantage Disadvantage
Hubert
et al. (92)
Patient-derived GBSC Microenvironmental impact and
cancer stem cell biology














hESC-derived cerebral organoid genetically
modified by introducing HRasG12V through
CRISPR/Cas9
Model for tumor formation and
transplantation













genetically modified by introducing several
mutation combinations through CRISPR/Cas9
GBM invasiveness and evaluation
of drug response
Personalized therapy Interactions between













Tumor sensitivity to radio-
chemotherapy
Interactions between







Co-culture of patient derived GBM stem cells
with hESC-derived cerebral organoid
GBM biology in the human brain
environment.
Drug screening
Tumor sensitivity to radio-
chemotherapy
Interactions between







GBM cells co-cultured with hESC-organoid cells Invasion and transcriptional
heterogeneity
Drug screening
Tumor sensitivity to radio-
chemotherapy
Interactions between







Patient-derived resected glioblastoma tumor
tissue
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Gómez-Oliva et al. Evolution of Experimental Models in the Study of Glioblastoma(GFAP) gene regulatory elements (77, 146), ii) aberrantly
activating the p21-RAS signaling pathway mimicking the effect
of EFGRvIII mutation (147, 148) to iii) overexpression of
IDH1R132H in the SVZ of the adult mouse brain (149).
In addition transduction of genes with viral vectors have been
used to efficiently reproduced GBM development: i) retroviruses
engineered to express relevant gain-of-function genes that result
from overexpression of the viral oncogene v-sis, the cellular
counterpart of which is c-sis or PDGF-B (73, 74); ii) adenovirus
containing the EGFRvIII mutant into mice harboring activated
RAS, which led to the efficient formation of glioblastoma (75); or
iii) lentivirus expressing oncogenes such as HRAS or AKT
(150, 151).
Models used in the study of GBM are the knockout of p53
tumor suppressor gene harboring a conditional allele of the
tumor suppressor Nf1 (152), a model that displays an
upregulation of Ras signaling; the Cdkn2a knockout mice
combined with Kras and Akt upregulation by viral induction
(74); the combination of both p53 and Cdkn2a knockout; the
introduction of EGFRvIII or Pten loss in the glioma-prone
mouse strain RasB8 mice with activated HRAS; the combined
conditional knockout of tumor suppressors p53, Nf1 and Pten
genes (151).
Genetically engineered or viral vector-mediated models offer
the ability to directly modify the genome of somatic cells in
mouse tissues (by targeting the genomic alterations driving
tumor behavior) for a rapid generation of complex mouse
tumor models, that harbor specific genetic alterations
providing the chance to potentially study specific drugs
interfering with the function of such genes (76, 77) (Figure 1D
and Table 1).
Canine Models
The use of canine models to understand GBM biology represents
a good option to simulate human conditions. The incidence of
brain tumors in dogs is high and its characteristics are similar to
those found in human (78, 79). Also, the comparison of GBM
histopathological features in dog versus those in murine models
leads to the conclusion of dog models as a good tool to perform
preclinical studies (80, 81). The advantages of using the canine
models of glioma are based on the similarities with human
gliomas including the presence of several neural precursor
markers such as nestin (82) and the capacity to form spheres
(78). In contrast, an intrinsic problem to its use is the difficulty of
detecting canine brain tumors and the ethical issues involved
and the need to comply with the 3R (refinement, replacement, and
reduction) for animal use in experimentation (Figure 1E and
Table 1).NOVEL TECHNICAL APPROACHES IN THE
STUDY OF GLIOBLASTOMA
As it can be inferred from the studies discussed above, in vitro
cell culture systems for the study of GBM do not exactly
reproduce the real conditions surrounding brain tumors andFrontiers in Oncology | www.frontiersin.org 9the use of animal models may not be the best approach either to
reproduce the particular niche in which GBM cells reside inside a
human brain. Thus, a refinement of the in vitro techniques was
required to produce humanized GBMmodels based on the three-
dimensional (3D) culture of GBM cells in a system that
reproduced the microenvironment of human brain tumors
(Figure 2).
2D vs 3D Co-Cultures
Studies on GBM require the culture of patient derived GBM
reproducing in vitro the conditions that establish interactions
between different types of cells and between the cells with the
extracellular matrix. GBM include a combination of fibroblasts,
endothelial cells, and stem cells that release signaling ligands that
determinate the characteristic. One of the challenges in cell culture
for GBM has been the search for coating elements that reproduce
these conditions as opposed to the effect of plastic. In this context a
collection of hydrogels have been produced from ECM derived
polymers that replicate the GBM microenvironment such
hyaluronic acid, chitosan, chondroitin sulfate polysaccharides,
alginates, and collagen/gelatin proteins (153). Matrigel (a mix of
mouse collagen, laminin, and ECM-associated growth factors) is a
hydrogel widely used in cultures of GBM, which allows cells to grow
interacting on multiple sides (154). However, these conditions do
not faithfully reflect the situation in vivo since proper tissue
architecture and cell-cell contacts may be lost in such 2D systems
as well as the contacts with the extracellular matrix.
Thus, recent works aimed to produce 3D GBM structures by
culturing GBM cells onto hydrogel coated 3D scaffolds in which
GSC or pieces of patient derived GBM are cultured reproducing a
more real tumor environment (Figure 2A). These systems
reproduce cell growth environment of GBM cells in
combination with more than one type of cell, soluble signaling
factors as well as the extracellular matrix signaling. Matrigel-
coated 3D polystyrene scaffolds have already been successfully
used to test drug efficacy (155), morphological structures in
human tumors (156) and invasion (reviewed in Caragher et al.,
2019) (154). The limitations of these scaffolds are the substrate
stiffness, the selection across passages of cells that attach more
loosely to the scaffold, which in turn are more invasive and
apparently show expression patterns more similar to GSC. Also,
the mouse origin of Matrigel makes it different from human
brain ECM and more humanized Matrigel is being developed
(154) together with other new promising biomaterials (157).
Microfluidic Technology in Glioblastoma
GBM tumors are structures surrounded by a constantly changing
microenvironment, which leads its development, however, the
particular invariable conditions of the medium in 3D cultures do
not reproduce this important attribute. Microfluidic technologies
solve the problem of GBM cells growing in static medium
(Figure 2B). These systems allow liquid media to be
continually delivered to growing cells (158, 159). GBM primary
cells can be grown in a scaffold of hydrogel tubes with circulating
medium. Cells are pumped into the tubes in a solution
containing brain ECM elements (160). The latest advances inJanuary 2021 | Volume 10 | Article 614295
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tissue for 3–7 days facilitating drug tests. As an example Olubajo
et al. fabricated a device using glass in a photolithographic
process, getting a high percentage (61.1%) of tissue viability
compared with fresh tissue at the beginning of the experiment
(68.9%) (159). This approach constitutes a new way to study
GBM progression since it replicates microenvironmental and
extracellular conditions prevailing in the brain and facilitates the
measurement of biological phenomena with high resolution and
in a high-throughput manner. In this context, Ayuso et al. used a
new microfluidic model in GBM to understand GBM
aggressiveness related to blood vessel obstruction. They studied
the area surrounding the necrotic part of the tumor usually
known as pseudopalisades finding a new method to study
nutrient and oxygen behavior in tumor progression and in the
migratory cell response (161).
All of these findings and promising methods have several
benefits such as the reproduction of the environmental
conditions typical of GBM, the generation of specific targeted
drug tests, and the possibility of keeping the tissue for longer
periods of time. On the contrary, it entails economic and time
cost and the search for the adequate materials to deliver the
microfluids depending on the type of study.
Organotypic Cultures
A new but not so novel approach in the study of GBM is the use of
organotypic cultures (Figure 2C andTable 1). These systems widely
used in other types of studies allow the transplantation of GBM cells
into brain slices that are kept alive for several weeks. This type of
organotypic cultures have already been used for the study of tumor
cell invasion the role of microglia in tumor growth and the niche
factors governing tumor growth (83–85). In addition,
microinjection of patient-derived tumor cells into cultured
sections the use of human slices allows the study of GBM
progression in its natural environment (86). This method enables
GBM cells to be grown surrounded by cells like those in the niche of
origin and therefore it is a good system to test microenvironmental
interaction, however, it does not reproduce the interactions with
blood flow factors or the hypoxic conditions.
Glioblastoma and Brain Organoids
Brain organoids are a promising new technology that has offered
new perspective for disease modelling, including cancer, in
human tissues (87, 162, 163). These brain like structures, so
called “mini-brains” provide a powerful tool for the ex vivo study
of the molecular and cellular mechanisms of human brain
disorders as they can accurately represent human organ
histology and physiology (87–89). Brain organoids involve the
generation of 3D tissues from pluripotent stem cells, such as
induced pluripotent stem cells and embryonic stem cells, or
adult-tissue-resident cells, that, in a controlled environment,
slowly grow and differentiate (Figure 2D and Table 1). This
architecture arises from the great self-organizing ability of these
cells to form whole tissues (90, 91). Brain organoids from
different regions are constructed resembling their in vivo
counterpart and recapitulating at least some functions found inFrontiers in Oncology | www.frontiersin.org 10vivo. Forebrain organoids exhibit the multi-layer progenitor zone
organization that recapitulates human cortical development,
including a prominent SVZ layer with radial glial cells-
exclusive expression of defined molecular markers. Besides,
these organoids present a diverse collection of functional
neuronal and other cell types found in developing human
brains. Midbrain and hypothalamic organoids from human
pluripotent stem cells have also been developed showing
specific neuronal markers found in vivo (164).
Based on this technology, several laboratories have attempted
to developed GBM models using different approaches:
As a first approach GBM specimens were embedded in
Matrigel and cultured in serum free conditions in the presence
of growth factors EGF and bFGF. This pioneering study proved
the suitability of this method to GBM studies (92). This organoid
model of GBM preserved important features of the original
tumor such as phenotypic heterogeneity among stem cells as
well as a hypoxic gradient that regulated stem cell mitotic
activity. Also, they successfully demonstrated its high
tumorigenic capacity after implantation in mouse brain. As an
alternative approach, da Silva et al. co-cultured human GBM
spheroids with early-stage brain organoids forming a hybrid
organoid with spontaneous infiltration of tumor cells into the
organoid demonstrating and invasive tumor phenotype (93).
A recent study has genetically engineered brain organoids to
generate a GBM model. Thus, Ogawa et al. generated a GBM
model organoid by entering the HRasG12V oncogene into
human brain organoids modifying the fourth exon of TP53
locus through CRISPR/Cas9. This mutated cell which profile
resembles the aggressive mesenchymal subtype of GBM,
proliferate and invade the normal organoid speedily. Besides,
in this work they also demonstrated that primary human-
patient-derived glioblastoma cell lines can be transplanted into
human cerebral organoids to induce tumors (94). In a related
study, Bian et al. introduce different oncogenic mutations found
in GBM into human cerebral organoids to study GBM pathology
and evaluate drug response (95).
Linkous et al. developed an organoid model by using patient-
derived glioma stem cells and human embryonic stem cell. This
model called GLICO showed that GSC move into the human
brain organoid invading and proliferating within the host tissue
and forming tumors that closely phenocopy patient GBMs (51).
Additionally, Krieger et al., co-cultured GBM cells with hESC-
organoid cells and showed that tumor cells within organoids
extend a network of long microtubes, recapitulating the in vivo
behavior of GBM. They also demonstrated that transcriptional
changes implicated in the invasion process are coherent across
patient samples, indicating that GBM cells reactively upregulate
genes required for their dispersion (96). In a different approach,
Hwang et al. generated a neuronal organoid model mimicking
GBM using induced pluripotent stem cells from a patient with c-
met mutation, a mutation in receptor for hepatocyte growth
factor involved in the progression and aggressiveness of
GBM (97).
Finally, a recent study by Jacob et al. generated and created a
live biobank of GBM organoids, called GBO, from fresh tumorJanuary 2021 | Volume 10 | Article 614295
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tumoral heterogeneity and key aspects of their corresponding
original tumors. These GBOs can be successfully transplanted
into the adult mouse brain with an aggressive and fast infiltration
profile and preserving original mutation expression (98). The
field of GBM organoids has rapidly developed years, we have
summarized in Table 3 how this type of studies have progressed
along the past four years from the first study by Hubert et al. (92)
to the more recent advances.
In general, this revolutionary and developing technology
reviewed by Zhang et al. (99) and summarize in Table 3,
provided its limitations such as the lack of vasculature,
immune cells or blood-brain barrier functions (100) has many
advantages in GBM studies because it allows to: i) analyze the
interactions between tumor and non-tumor cells (94, 95), ii)
functionally analyze the consequences of genome aberrations
within the same genetic background (94, 95), iii) study the
interactions between tumor cells and their microenvironment,
iv) test the susceptibility of individuals to different combinations
of driver mutations (95, 97), and v) design personalized therapies
and treatments (94, 97, 98). Related to the potential use of
organoids to evaluate GBM treatment response, there are some
ongoing promising trials in other cancers that demonstrated
their powerful and utility. The use of this approach is especially
important in cancer treatment due to the inherent resistance of
cancer cells and the different response to the treatment among
patients. Vlachogiannis et al. demonstrated that cultured cancer-
derived organoids from patients with gastrointestinal metastatic
cancers treated with a broad set of anticancer agents could
retrospectively predict response with an 88% positive
predictive value and 100% negative predictive value using a
generalized cell viability assay (101). Several clinical studies
showed the feasibility of testing patient-derived tumor
organoids for evaluation of sensitivity to chemotherapy (102,
103) and radiation. Ooft et al., demonstrated that patient-derived
tumor organoids predicted response of the biopsied lesion in
more than 80% of metastatic colorectal cancer patients treated
with irinotecan-based therapies without misclassifying patients
who would have benefited from treatment (102). Therefore,
organoid models are not only very useful for studies of
essential tumor biology, but also they are suitable for
preclinical investigations, such us drug screening and analysis
of antitumor effects accompanied by a rapid and safety test in the
same system (104).
3D Bioprinting in Glioblastoma
Three dimensional biological constructions (3D bioprinting)
represent a new and promising method of study not only in
GBM but also in other types of diseases (Figure 2E). Layers of
biomaterials are deposited generating an extracellular matrix,
which contains live cells of different types organized into a cell
network resembling the real tumor in a very faithful way (105).
Particularly, most studies on 3D bioprinting of GBM have been
used to study the role of glioblastoma-associated macrophages
(GAMs), which are key cells in tumor progression, angiogenesis
and also in invasiveness (165–167). The advantage of 3D
bioprinting resides in the possibility to replicate the architectureFrontiers in Oncology | www.frontiersin.org 11of tissues being crucial to test drugs effectively and also, fulfilling
the principle of 3R of animal experimentation (106).
This technology allows the creation of a “mini-brain” in the
form of 3D bioprinting model and although it is not a real
representation owing to the lack of stem cells, the model includes
a combination of different types of cells that are able to interact
with each other. The technique is based on bioprinting a brain
model using mouse macrophages which is then filled with mouse
glioblastoma cells (GL261). The resulting model is adequate to
test chemotherapeutic agents as well as macrophage modulating
drugs (106). Other authors such as Hermida et al. used another
bioprinting method to produce multilineage GBM models (109)
and reveal that it is an advantageous method to test drugs and to
perform cell signaling analysis using fluorescence-bound protein
kinase reporters. Other authors use biomaterials such as
hyaluronic acid (HA)-based hydrogels and also, synthetic
polymers such as polyethylene-glycol (107, 108).
Furthermore, Tang et al. analyzed 3D printed GBM
macrophages in combination with GSC alone or in combination
with astrocytes and NPC. They identified molecular characteristics
of GSC and evidenced the use of this type of model as an important
approach for drug sensibility scanning, the study of invasion,
immunologic interactions, and cellular crosstalk (110).
Advances in 3D bioprinting have represented a new vision in
the discovery of effective drugs for this type of pathologies, but
there are also disadvantages that must be taken into
consideration. One is the materials required to print, which
may not be physiological molecules. Also, it is necessary to
improve the current resolution of printing in order to
introduce vasculature (106). Comparing with other methods
raised above, the 3D bioprinting is the most adequate when it
comes to analyzing the interactions between cells and also to
understand the microenvironment created within the tumor
(Figure 2E and Table 1).FUTURE DIRECTIONS
Despite the greatest advances made within the field, GBM is still
a highly malignant tumor, resistant to the currently available
treatments. Research in the field of GBM should not only be
guided towards understanding the behavior of the tumors, but
also towards the finding of a new and effective medication.
Therefore, the development of experimental models in the
study of GBM should be focused on those that facilitate the
discovery of new and more potent therapeutic options. In this
context, attention needs to be paid to therapies directed to
exploiting the potential of the immune system (70, 71). Future
experimental models in the study of GBM would need to allow
the study of the crosstalk between GBM and the components of
the immune system in order to facilitate the development of
immune based therapies. In addition, techniques such as GBM
organoids that allow the understanding of the individual
behavior of each tumor as well as the screening of the available
pharmacological options for each individual tumor would be
those preferably developed in the short future.January 2021 | Volume 10 | Article 614295
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As time has passed since the first discoveries and advances in the
study of GBM using cultures of cells (patient-derived cells and
GBM cells lines), and mouse models (xenograft, genetically
engineered and viral vector-mediated transduction models)
new techniques are now defining the future of GBM studies,
which will probably be characterized by the use of individual
organoids combined with single cell sequencing of genetic
alterations to understand the processes involved in GBM origin
and development. Also, the combination of different techniques,
such as organotypic cultures and organoids, with 3D bioprinting
could lead to an improvement in the study of cell interactions in
GBM. Using all these latest scientific advances, targeted therapies
can be tested and designed specifically for each patient resulting
in a better prognosis and shedding light into the mechanisms
controlling this devastating disease.AUTHOR CONTRIBUTIONS
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Gómez-Oliva et al. Evolution of Experimental Models in the Study of Glioblastomaanalysis of prospective studies. PLoS One (2013) 8(5):e63682. doi: 10.1371/
journal.pone.0063682
21. Garzon-Muvdi T, Kut C, Li X, Chaichana KL. Intraoperative imaging
techniques for glioma surgery. Future Oncol (2017) 13(19):1731–45. doi:
10.2217/fon-2017-0092
22. Lau D, Magill ST, Aghi MK. Molecularly targeted therapies for recurrent
glioblastoma: current and future targets. Neurosurg Focus (2014) 37(6):E15.
doi: 10.3171/2014.9.FOCUS14519
23. Chen J, Li Y, Yu TS, McKay RM, Burns DK, Kernie SG, et al. A restricted cell
population propagates glioblastoma growth after chemotherapy. Nature
(2012) 488(7412):522–6. doi: 10.1038/nature11287
24. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, et al. Glioma stem
cells promote radioresistance by preferential activation of the DNA damage
response. Nature (2006) 444(7120):756–60. doi: 10.1038/nature05236
25. Lathia JD, Mack SC, Mulkearns-Hubert EE, Valentim CL, Rich JN. Cancer
stem cells in glioblastoma. Genes Dev (2015) 29(12):1203–17. doi: 10.1101/
gad.261982.115
26. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, et al.
Identification of a cancer stem cell in human brain tumors. Cancer Res
(2003) 63(18):5821–8.
27. Beier D, Hau P, Proescholdt M, Lohmeier A, Wischhusen J, Oefner PJ, et al.
CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show
differential growth characteristics and molecular profiles. Cancer Res
(2007) 67(9):4010–5. doi: 10.1158/0008-5472.CAN-06-4180
28. Neradil J, Veselska R. Nestin as a marker of cancer stem cells. Cancer Sci
(2015) 106(7):803–11. doi: 10.1111/cas.12691
29. Strojnik T, Rosland GV, Sakariassen PO, Kavalar R, Lah T. Neural stem cell
markers, nestin and musashi proteins, in the progression of human glioma:
correlation of nestin with prognosis of patient survival. Surg Neurol (2007)
68(2):133–43; discussion 43-4. doi: 10.1016/j.surneu.2006.10.050
30. Capela A, Temple S. LeX is expressed by principle progenitor cells in the
embryonic nervous system, is secreted into their environment and binds
Wnt-1. Dev Biol (2006) 291(2):300–13. doi: 10.1016/j.ydbio.2005.12.030
31. Liu XY, Gerges N, Korshunov A, Sabha N, Khuong-Quang DA, Fontebasso
AM, et al. Frequent ATRX mutations and loss of expression in adult diffuse
astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. Acta
Neuropathol (2012) 124(5):615–25. doi: 10.1007/s00401-012-1031-3
32. Heddleston JM, Li Z, McLendon RE, Hjelmeland AB, Rich JN. The hypoxic
microenvironment maintains glioblastoma stem cells and promotes
reprogramming towards a cancer stem cell phenotype. Cell Cycle (2009) 8
(20):3274–84. doi: 10.4161/cc.8.20.9701
33. Piccirillo SG, Spiteri I, Sottoriva A, Touloumis A, Ber S, Price SJ, et al.
Contributions to drug resistance in glioblastoma derived from malignant
cells in the sub-ependymal zone. Cancer Res (2015) 75(1):194–202. doi:
10.1158/0008-5472.CAN-13-3131
34. Piccirillo SG, Sottoriva A, Watts C. The role of sub-ventricular zone in
gliomagenesis. Aging (Albany NY) (2015) 7(10):738–9. doi: 10.18632/
aging.100823
35. Lee JH, Lee JE, Kahng JY, Kim SH, Park JS, Yoon SJ, et al. Human
glioblastoma arises from subventricular zone cells with low-level driver
mutations. Nature (2018) 560(7717):243–7. doi: 10.1038/s41586-018-0389-3
36. Charles N, Holland EC. The perivascular niche microenvironment in brain
tumor progression. Cell Cycle (2010) 9(15):3012–21. doi: 10.4161/
cc.9.15.12710
37. Mohyeldin A, Garzon-Muvdi T, Quinones-Hinojosa A. Oxygen in stem cell
biology: a critical component of the stem cell niche. Cell Stem Cell (2010) 7
(2):150–61. doi: 10.1016/j.stem.2010.07.007
38. Folkins C, Shaked Y, Man S, Tang T, Lee CR, Zhu Z, et al. Glioma tumor
stem-like cells promote tumor angiogenesis and vasculogenesis via vascular
endothelial growth factor and stromal-derived factor 1. Cancer Res (2009) 69
(18):7243–51. doi: 10.1158/0008-5472.CAN-09-0167
39. Sanai N, Tramontin AD, Quinones-Hinojosa A, Barbaro NM, Gupta N,
Kunwar S, et al. Unique astrocyte ribbon in adult human brain contains
neural stem cells but lacks chain migration. Nature (2004) 427(6976):740–4.
doi: 10.1038/nature02301
40. Quinones-Hinojosa A, Sanai N, Soriano-Navarro M, Gonzalez-Perez O,
Mirzadeh Z, Gil-Perotin S, et al. Cellular composition and cytoarchitectureFrontiers in Oncology | www.frontiersin.org 13of the adult human subventricular zone: a niche of neural stem cells. J Comp
Neurol (2006) 494(3):415–34. doi: 10.1002/cne.20798
41. Robertson FL, Marques-Torrejon MA, Morrison GM, Pollard SM.
Experimental models and tools to tackle glioblastoma. Dis Model Mech
(2019) 12(9). doi: 10.1242/dmm.040386
42. Fields KL, Gosling C, Megson M, Stern PL. New cell surface antigens in rat
defined by tumors of the nervous system. Proc Natl Acad Sci U S A (1975) 72
(4):1296–300. doi: 10.1073/pnas.72.4.1296
43. Sundarraj N, Schachner M, Pfeiffer SE. Biochemically differentiated mouse
glial lines carrying a nervous system specific cell surface antigen (NS-1). Proc
Natl Acad Sci U S A (1975) 72(5):1927–31. doi: 10.1073/pnas.72.5.1927
44. de Ridder LI, Laerum OD, Mork SJ, Bigner DD. Invasiveness of human
glioma cell lines in vitro: relation to tumorigenicity in athymic mice. Acta
Neuropathol (1987) 72(3):207–13. doi: 10.1007/BF00691091
45. Notarangelo A, Trombetta D, D’Angelo V, Parrella P, Palumbo O, Storlazzi
CT, et al. Establishment and genetic characterization of ANGM-CSS, a
novel, immortal cell line derived from a human glioblastoma multiforme. Int
J Oncol (2014) 44(3):717–24. doi: 10.3892/ijo.2013.2224
46. Weeber F, Ooft SN, Dijkstra KK, Voest EE. Tumor Organoids as a Pre-
clinical Cancer Model for Drug Discovery. Cell Chem Biol (2017) 24
(9):1092–100. doi: 10.1016/j.chembiol.2017.06.012
47. Torsvik A, Stieber D, Enger PO, Golebiewska A, Molven A, Svendsen A,
et al. U-251 revisited: genetic drift and phenotypic consequences of long-
term cultures of glioblastoma cells. Cancer Med (2014) 3(4):812–24. doi:
10.1002/cam4.219
48. Allen M, Bjerke M, Edlund H, Nelander S, Westermark B. Origin of the
U87MG glioma cell line: Good news and bad news. Sci Trans Med (2016) 8
(354):354re3. doi: 10.1126/scitranslmed.aaf6853
49. Sottoriva A, Spiteri I, Piccirillo SG, Touloumis A, Collins VP, Marioni JC,
et al. Intratumor heterogeneity in human glioblastoma reflects cancer
evolutionary dynamics. Proc Natl Acad Sci U S A (2013) 110(10):4009–14.
doi: 10.1073/pnas.1219747110
50. Jiang J, Qiu J, Li Q, Shi Z. Prostaglandin E2 Signaling: Alternative Target for
Glioblastoma? Trends Cancer (2017) 3(2):75–8. doi: 10.1016/
j.trecan.2016.12.002
51. Linkous A, Balamatsias D, Snuderl M, Edwards L, Miyaguchi K, Milner T,
et al. Modeling Patient-Derived Glioblastoma with Cerebral Organoids. Cell
Rep (2019) 26(12):3203–11. doi: 10.1016/j.celrep.2019.02.063
52. Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin NM, et al. Tumor stem
cells derived from glioblastomas cultured in bFGF and EGF more closely
mirror the phenotype and genotype of primary tumors than do serum-
cultured cell lines. Cancer Cell (2006) 9(5):391–403. doi: 10.1016/
j.ccr.2006.03.030
53. Brewer GJ, Torricelli JR, Evege EK, Price PJ. Optimized survival of
hippocampal neurons in B27-supplemented Neurobasal, a new serum-free
medium combination. J Neurosci Res (1993) 35(5):567–76. doi: 10.1002/
jnr.490350513
54. Baskaran S, Mayrhofer M, Kultima HG, Bergstrom T, Elfineh L, Cavelier L,
et al. Primary glioblastoma cells for precision medicine: a quantitative
portrait of genomic (in)stability during the first 30 passages. Neuro Oncol
(2018) 20(8):1080–91. doi: 10.1093/neuonc/noy024
55. Jayakrishnan PC, Venkat EH, Ramachandran GM, Kesavapisharady KK,
Nair SN, Bharathan B, et al. In vitro neurosphere formation correlates with
poor survival in glioma. IUBMB Life (2019) 71(2):244–53. doi: 10.1002/
iub.1964
56. Wang J, Wakeman TP, Lathia JD, Hjelmeland AB, Wang XF, White RR,
et al. Notch promotes radioresistance of glioma stem cells. Stem Cells (2010)
28(1):17–28. doi: 10.1002/stem.261
57. Chen J, McKay RM, Parada LF. Malignant glioma: lessons from genomics,
mouse models, and stem cells. Cell (2012) 149(1):36–47. doi: 10.1016/
j.cell.2012.03.009
58. Mori H, Ninomiya K, Kino-oka M, Shofuda T, IslamMO, Yamasaki M, et al.
Effect of neurosphere size on the growth rate of human neural stem/
progenitor cells. J Neurosci Res (2006) 84(8):1682–91. doi: 10.1002/jnr.21082
59. Ladiwala U, Basu H, Mathur D. Assembling neurospheres: dynamics of
neural progenitor/stem cell aggregation probed using an optical trap. PLoS
One (2012) 7(6):e38613. doi: 10.1371/journal.pone.0038613January 2021 | Volume 10 | Article 614295
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